Anchiano Therapeutics Ltd. (NASDAQ: ANCN, TASE: ANCN) was founded on September 22, 2011, formerly known as BioCancell Therapeutics Inc., changed its current name in August 2018, headquartered in Jerusalem, Israel, and has 17 full-time employees ( 9/30/2018), is a clinical-stage biopharmaceutical company dedicated to designing targeted gene therapies to improve the standard treatment of early bladder cancer (one of the most common cancers).
Anchiano Therapeutics Ltd. (ANCN):
Anchiano Therapeutics Ltd. was incorporated under the laws of the State of Israel on September 22, 2011 for the purpose of reorganization and merger, combining BioCancell Therapeutics Inc. (BTI) with its wholly-owned subsidiary BioCancell Ltd. (BioCancell). BTI was incorporated in the United States under the laws of Delaware on July 26, 2004, and began commercial operations on October 1, 2004. The reorganization was completed on August 14, 2012, and BTI continued to exist as a wholly-owned subsidiary of BioCancell until it was officially dissolved in Delaware on December 28, 2012. In August 2018, BioCancell was renamed Anchiano Therapeutics Ltd..
Anchiano Therapeutics has discovered and is developing a biological agent called inodiftagene vixteplasmid (inodiftagene). The company believes that it can provide new treatments for patients with limited treatment options and greater side effects. Bladder cancer is a disease that usually causes symptoms early in its course, thus giving patients and treating physicians an opportunity to control malignant tumors. However, the limitations of existing therapies (developed in the 1970s) often lead to a series of unsuccessful treatments that could have ended with radical cure for bladder cancer.
Anchiano Therapeutics’ main product candidate, inodiftagene, is a recombinant DNA construct that can be used for the treatment of early bladder cancer: this is a gene therapy for bladder cancer. The pre-clinical studies and clinical trials completed so far have proven that Anchiano Therapeutics’ product candidates can specifically deliver lethal genes to bladder cancer cells in the bladder of patients. Based on the company’s Phase I and Phase II clinical trials, Anchiano Therapeutics believes that its product candidate inodiftagene may significantly improve the prognosis of patients by delaying or in some cases eliminating disease progression, thereby significantly improving the quality of life of patients .
Although there is no guarantee that the TV is based on the interaction of Anchiano Therapeutics with the US Food and Drug Administration and other international regulatory agencies, the company believes that the clinical trial plan completed so far has laid the foundation for the approved commercialization and widespread use of its candidate products. The clinical development plan proposed by the company includes two key clinical studies to address related but different indications.
Anchiano Therapeutics’ main product candidate, inodiftagene, is a biological agent whose design and formulation can transmit toxic genes in bladder cells, causing the gene to be active only in bladder tumors, thereby killing only malignant cells. The engineered gene has been mixed with an agent that enhances and optimizes its delivery efficiency to tissues. In experiments, the company has proven that after a single dose, 85% of target cells take up inodiftagene.
Anchiano Therapeutics tested inodiftagene in six clinical trials, three of which involved NMIBC patients, and we observed substantial anti-tumor activity. Data from the three phase I/II and phase II trials of NMIBC show that inodiftagene caused a complete response in 33% of bladder cancer patients with unresected measurable tumors; the one-year and two-year recurrence-free survival rates were 46%, respectively And 33%; and the company used BCG (NMIBC’s current standard of care) combined with inodiftagene, and the recurrence-free results at 3 and 6 months were 95% and 78%, respectively.
Anchiano Therapeutics Ltd. (ANCN) investment:
Anchiano Therapeutics Ltd. (NASDAQ:ANCN, TASE:ANCN) submitted its IPO prospectus on 1/7/2019 and listed on NASDAQ on 2/12/2019. The planned issue price is $14.55, the actual issue price is $10.5, and the issue is 240. 10,000 shares, raised US$25.2 million, underwritten by Oppenheimer.